Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines

Open access
Al Khaja, Khalid A. J., Sequeira, Reginald P. · 2021 · Malaria Journal

Abstract

Background: Malaria caused by Plasmodium falciparum in pregnancy can result in adverse maternal and fetal sequelae. This review evaluated the adherence of the national guidelines drawn from World Health Organization (WHO) regions, Africa, Eastern Mediterranean, Southeast Asia, and Western Pacific, to the WHO recommendations on drug treatment and prevention of chloroquine-resistant falciparum malaria in pregnant women. Methods: Thirty-five updated national guidelines and the President’s Malaria Initiative (PMI), available in English language, were reviewed. The primary outcome measures were the first-line anti-malarial treatment protocols adopted by national guidelines for uncomplicated and complicated falciparum malaria infections in early (first) and late (second and third) trimesters of pregnancy. The strategy of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) was also addressed. Results: This review evaluated the treatment and prevention of falciparum malaria in pregnancy in 35 national guidelines/PMI-Malaria Operational Plans (MOP) reports out of 95 malaria-endemic countries. Of the 35 national guidelines, 10 (28.6%) recommend oral quinine plus clindamycin as first-line treatment for uncomplicated malaria in the first trimester. As the first-line option, artemether–lumefantrine, an artemisinin-based combination therapy, is adopted by 26 (74.3%) of the guidelines for treating uncomplicated or complicated malaria in the second and third trimesters. Intravenous artesunate is approved by 18 (51.4%) and 31 (88.6%) guidelines for treating complicated malaria during early and late pregnancy, respectively. Of the 23 national guidelines that recommend IPTp-SP strategy, 8 (34.8%) are not explicit about directly observed therapy requirements, and three-quarters, 17 (73.9%), do not specify contra-indication of SP in human immunodeficiency virus (HIV)-infected pregnant women receiving cotrimoxazole prophylaxis. Most of the guidelines (18/23; 78.3%) state the recommended folic acid dose. Conclusion: Several national guidelines and PMI reports require update revisions to harmonize with international guidelines and emergent trends in managing falciparum malaria in pregnancy. National guidelines and those of donor agencies should comply with those of WHO guideline recommendations although local conditions and delayed guideline updates may call for deviations from WHO evidence-based guidelines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12936-020-03565-2

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 2

  1. WHO. Guidelines for the treatment of malaria, 2nd Edn. Geneva, World Health Organization, 2010. https://www.ncbi.nlm.nih.gov/books/NBK254223/. Accessed 5 Jun 2020.
  2. Management Sciences for Health (MSH)/WHO. International Medical Products Price Guide. 2015 edition. https://www.msh.org/sites/default/files/msh-2015-international-medical-products-price-guide.pdf. Accessed 7 Jun 2020.

Cited by

See all 39

Metadata

Authors
Al Khaja, K. A. J., & Sequeira, R. P.
Affiliations
Arabian Gulf University (BH)
Venue
Malaria Journal
Published
2021-01-23
Volume
20
Issue
1
Pages
62-62
ISSN
1475-2875 (ISSN-L)
OpenAlex
W3121915585
Cited by
39
References
54
Citations by year
2026: 1 · 2025: 10 · 2024: 12 · 2023: 7 · 2022: 6 · 2021: 3
FWCI
1.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Malaria Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Global Maternal and Child Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
Keywords
malaria in pregnancy, Plasmodium falciparum, chloroquine resistance, national treatment guidelines, WHO guidelines, artemether-lumefantrine, artesunate, sulfadoxine-pyrimethamine, intermittent preventive treatment, quinine, HIV coinfection, folic acid supplementation, guideline adherence, President's Malaria Initiative, malaria prevention in pregnancy
MeSH terms
Artesunate, Artemether, Artemether, Lumefantrine Drug Combination, Adult, Antimalarials, Chloroquine, Drug Combinations, Female, Humans, Malaria, Pregnancy, Pyrimethamine, Quinine, Sulfadoxine, Pregnancy Complications, Parasitic, Practice Guidelines as Topic, Parasitemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines. https://app.cochat.ai/papers/10.1186/s12936-020-03565-2
The paper
Al Khaja, K. A. J., & Sequeira, R. P. (2021). Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines. Malaria Journal. https://doi.org/10.1186/s12936-020-03565-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.